Catalent saw a welcome improvement to its Relative Strength (RS) Rating on Thursday before the open, rising from 66 to 75.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating measures share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest runs. See if Catalent can continue to show renewed price strength and clear that threshold.
Looking For The Best Stocks To Buy And Watch? Start Here
While the stock is not near a proper entry right now, it has cleared some key moving averages. One big hurdle left on that regard - 200 day moving average. Let's see if it goes on to form and break out from a proper chart pattern.
Catalent Stock posted 27% EPS growth in its most recent report. Sales gains came in at 21%.
Catalent holds the No. 1 rank among its peers in the Medical-Research Equipment/Services industry group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
